Results of autologous and allogeneic hematopoietic cells transplant therapy for multiple myeloma

Bone Marrow Transplantation

Volumn 35, Issue 12, 2005, Pages 1133-1140

  Arora, M ^a   McGlave, P B ^a   Burns, L J ^a   Miller, J S ^a   Barke, J N ^a   Defor, T E ^a   Weisdorf, D J ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Autologous vs allogeneic; Multiple myeloma; PBSCT

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXAMETHASONE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MELPHALAN; METHOTREXATE; MITOXANTRONE;

ADULT; AGED; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER RELAPSE; CANCER SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG TOLERABILITY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE MYELOMA; MYELOABLATIVE CONDITIONING; OUTCOMES RESEARCH; PRIORITY JOURNAL; SURVIVAL RATE; TRANSPLANTATION TOLERANCE;

ADULT; AGED; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MYELOABLATIVE AGONISTS; PROGNOSIS; REMISSION INDUCTION; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 21244451097     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704968     Document Type: Article

References (17)

1. Attal M, Harousseau JL, Stoppa AM et al. A prospective randomized trial of autologous transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91-97.
2. Bjorkstrand B. The European group for blood and marrow transplantation registry studies in multiple myeloma. Semin Hematol 2001; 38: 219-225.
3. 2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 2002; 99: 731-735.
4. Barlogie B, Jagannath S, Desikan KR et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55-65.
5. Attal M, Harousseau JL, Facon T et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495-2502.
6. Tricot G, Spencer T, Sawyer J et al. Predicting long term (>or-5 years) event free survival in multiple myeloma patients following planned tandem autotransplants. Br J Haematol 2002; 116: 211-217.
7. Gahrton G, Svensson H, Cavo M et al. European Group for Blood and Marrow Transplantation. Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-98 at the European Group for Blood and Marrow Transplantation centers. Br J Haematol 2001; 113: 209-216.
8. Bjorkstrand BB, Ljungman P, Svensson H et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 1996; 88: 4711-4718.
9. Maloney DG, Molina AJ, Sahebi F et al. Allografting with non-myeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003; 102: 3447-3454.
10. Arora M, Burns LJ, Barker JN et al. Randomized comparison of G-CSF versus GM-CSF +intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. Biol Blood Marrow Transplant 2004; 10: 395-404.
11. Anderson D, DeFor T, Burns L et al. A comparison of related donor peripheral blood and bone marrow transplants: importance of late-onset chronic graft-versus-host disease and infections. Biol Blood Marrow Transplant 2003; 9: 52-59.
12. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
13. Cox DR. Regression models and life tables. J R Stat Soc B 1972; 34: 187-220.
14. Lin DY. Non-parametric inference for cumulative incidence functions in competing risks studies. Stat Med 1997; 16: 901-910.
15. Desikan R, Barlogie B, Sawyer J et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 2000; 95: 4008-4010.
16. Child JA, Morgan GJ, Davies FE et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883.
17. Segeren CM, Sonneveld P, van der Holt B et al. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. Blood 2003; 101: 2144-2151.